Clinical Trial Update: Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing CDK4/6 inhibitors for chemo-refractory, RB wild-type extensive small-cell lung cancer. The study also includes extrapulmonary s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Small Cell Carcinoma
• Large Cell Neuroendocrine Carcinoma of the Lung
• Small Cell Lung Cancer

Drugs mentioned

• CDK4/6 inhibitors

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung | Phase 2 | Status: ACTIVE_NOT_RECRUITING